Feature: Taking the Risk and Volatility Out of Merck.

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Feature: Taking the Risk & Volatility Out of Merck Once you've absorbed this risk-reduction strategy, it could well be applied to almost any optionable stock, ETF or index. With the second Vioxx trial now underway, Merck (NYSE: MRK) is once again in the
Feature: Blowing Bubbles. Novelos Collaborates. Coverages Dropped.

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Feature: Blowing Bubbles. Novelos Collaborates. Coverages Dropped. Investing rule number one: Every market corrects. Investing rule number two: Read rule number one. The ugly stepsister of the growing economy is the current obscene level of consumer debt
Feature: Novelos - Use Pullback to Acquire Shares.

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Feature: Novelos - Use Pullback to Acquire Shares. We strongly feel that the recent pullback in Novelos Therapeutics (OTCBB: NVLT) from $4.50 to $3.20--for no reason we can ascertain-- represents a great strategic opportunity for investors to accumulate
Feature: MIV Therapeutics - Impressive Rally. More Patents Filed.

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Feature: MIV Therapeutics - Impressive Rise. More Patents Filed. In March 2005, we were already convinced of the potential for biotech and medical device company MIV Therapeutics (OTCBB: MIVT) when we Alerted the readership to the shares at 34 cents. How
Feature: Profiting From Controversy - The Vioxx Trade(s).

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Feature: Profiting From Controversy - The Vioxx Trade(s). There's little doubt that the Vioxx controversy has been bad for everyone: patients, families, Merck, (NYSE: MRK) its shareholders, the drug sector and the markets. In no way is this piece biased
<<287  288  289  290  291  292  293  294  295  296  >>